ArticleFrontiers in oncology2021

Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.

Bei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.